Table 2.
Characteristics and Outcomes of Participants (n=58) with a Final Diagnosis of Acetaminophen Toxicity
| Age (Years) | n(%) | 
|---|---|
| <1 | 2(3) | 
| 1–2 | 1(2) | 
| 3–9 | 4(7) | 
| 10–17 | 51(88) | 
| Gender | |
| Female | 46(79) | 
| Ethnicity | |
| Hispanic or Latino | 5(9) | 
| Race | |
| White | 44(77) | 
| African American | 5(9) | 
| Other | 8(14) | 
| Hepatic Encephalopathy at Enrollment | |
| Grade II or less | 51 | 
| Grade III or IV | 7 | 
| Laboratory Value Median (25%– 75%) | |
| Alanine Aminotransferase IU/L (n=55) | 5305(3371–7771) | 
| Aspartate Aminotransferase IU/L (n=58) | 4053(2022–7605) | 
| Total Bilirubin mg/dL (n=58) | 2.2(1.2–3.1) | 
| Direct Bilirubin mg/dL (n=51) | 0.6(0.3–1.2) | 
| International Normalized Ratio (n=53) | 2.3(1.7–3.7) | 
| Creatinine mg/dL (n=57) | 0.7(0.6–1.1) | 
| 21 day Outcome | |
| Death without Transplantation | 2(3.5%) | 
| Transplantation | 3(5.2%) | 
| Spontaneous Survival | 53(91.4%) |